Bank of America
CRBP icon

Bank of America’s Corbus Pharmaceuticals CRBP Stock Holding History

Bank of America’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$131K Buy
13,960
+13,934
+53,592% +$117K ﹤0.01% 5478
2025
Q4 		$212 Sell
26
-54,635
-100% -$674K ﹤0.01% 6685
2025
Q3 		$691K Sell
54,661
-17,232
-24% -$164K ﹤0.01% 5577
2025
Q2 		$496K Buy
71,893
+55,314
+334% +$402K ﹤0.01% 5714
2025
Q1 		$88K Sell
16,579
-14,896
-47% -$131K ﹤0.01% 6545
2024
Q4 		$371K Buy
31,475
+7,207
+30% +$121K ﹤0.01% 5760
2024
Q3 		$501K Sell
24,268
-28,819
-54% -$1.47M ﹤0.01% 5481
2024
Q2 		$2.4M Buy
53,087
+25,092
+90% +$1.06M ﹤0.01% 4299
2024
Q1 		$1.1M Buy
27,995
+27,991
+699,775% +$690K ﹤0.01% 4874
2023
Q4 		$24 Buy
+4
New +$21 ﹤0.01% 7622
2023
Q3 		– Sell
-1
Closed -$8 – 7787
2023
Q2 		$8 Hold
1
– – ﹤0.01% 7573
2023
Q1 		$7 Sell
1
-11
-92% -$48 ﹤0.01% 7657
2022
Q4 		$39 Buy
12
+7
+140% +$27 ﹤0.01% 7846
2022
Q3 		$0 Buy
5
+3
+150% +$21 ﹤0.01% 7885
2022
Q2 		$0 Hold
2
– – ﹤0.01% 8063
2022
Q1 		$0 Sell
2
-22
-92% -$292 ﹤0.01% 8325
2021
Q4 		$0 Sell
24
-21,756
-100% -$589K ﹤0.01% 8268
2021
Q3 		$666K Buy
21,780
+19,377
+806% +$764K ﹤0.01% 5414
2021
Q2 		$132K Sell
2,403
-70
-3% -$3.88K ﹤0.01% 6354
2021
Q1 		$146K Buy
2,473
+1,285
+108% +$84.5K ﹤0.01% 6233
2020
Q4 		$44K Sell
1,188
-5,634
-83% -$211K ﹤0.01% 6369
2020
Q3 		$368K Buy
6,822
+5,524
+426% +$1M ﹤0.01% 4943
2020
Q2 		$327K Buy
1,298
+646
+99% +$131K ﹤0.01% 4929
2020
Q1 		$103K Buy
652
+47
+8% +$7.95K ﹤0.01% 5512
2019
Q4 		$99K Sell
605
-258
-30% -$38.1K ﹤0.01% 5998
2019
Q3 		$126K Sell
863
-38
-4% -$6.62K ﹤0.01% 5930
2019
Q2 		$187K Sell
901
-1,748
-66% -$374K ﹤0.01% 5674
2019
Q1 		$552K Buy
2,649
+1,406
+113% +$310K ﹤0.01% 4949
2018
Q4 		$218K Buy
1,243
+77
+7% +$15.4K ﹤0.01% 5463
2018
Q3 		$264K Buy
1,166
+804
+222% +$130K ﹤0.01% 5332
2018
Q2 		$55K Sell
362
-89
-20% -$16.2K ﹤0.01% 6096
2018
Q1 		$83K Sell
451
-62
-12% -$13.9K ﹤0.01% 5819
2017
Q4 		$109K Buy
513
+417
+434% +$89.3K ﹤0.01% 5705
2017
Q3 		$21K Buy
96
+73
+317% +$14.3K ﹤0.01% 6248
2017
Q2 		$4K Buy
+23
New +$4.51K ﹤0.01% 6638
2016
Q4 		– Sell
-33
Closed -$7K – 7073
2016
Q3 		$7K Buy
+33
New +$4.11K ﹤0.01% 6489
2016
Q2 		– Hold
0
– – – 7155

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America's CRBP Position: Q1 2026 in Review

Bank of America increased its Corbus Pharmaceuticals (CRBP) stake by 53,592% in Q1 2026, buying an estimated $117K and bringing the position to 13,960 shares worth $131K. The position accounts for ﹤0.01% of the portfolio, ranked #5478.

Bank of America first reported a position in CRBP in Q3 2016 and has held it in 36 quarters since. The position peaked at $2.4M in Q2 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • Bank of America held 13,960 shares of Corbus Pharmaceuticals worth $131K as of Q1 2026.
  • Bank of America bought 13,934 Corbus Pharmaceuticals shares in Q1 2026, an estimated $117K.
  • Corbus Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5478 holding.
  • Bank of America first reported a position in Corbus Pharmaceuticals in Q3 2016 and has held it in 36 quarters since.
  • Bank of America's Corbus Pharmaceuticals position peaked at $2.4M in Q2 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.